Education
About Us
Working with TipRanks
Follow Us
Collegium Pharmaceutical (COLL)
NASDAQ:COLL
Earnings Data
Report Date
May 07, 2026TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
1.81Last Year’s EPS
1.49Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasizes strong, broad-based commercial performance (notably Jornay PM) and robust financial outcomes for 2025 — record revenue, record adjusted EBITDA, strong cash generation, and materially improved leverage. Management reiterated disciplined capital deployment, added liquidity via a $980M syndicated facility, and expects Jornay to be a key growth driver in 2026 (guiding Jarday revenue +~31% YoY). However, near-term headwinds and risks include substantial increases in operating expenses due to commercialization investments, elevated gross-to-net rates (≈64%), expected seasonal Q1 pressure, a Q4 decline in Xtampza, and the impact of an authorized generic for Nucynta (partially mitigated by profit share). Overall, the positives (revenue growth, cash flow, leverage improvement, Jornay momentum, strategic financing) materially outweigh the lowlights, which are largely investment- and seasonality-driven.Company Guidance
Record Full-Year Revenue and Adjusted EBITDA
Full-year 2025 net revenues of $780.6M, up 24% year-over-year, and record adjusted EBITDA of $460.5M, up 15% year-over-year.
Strong Cash Generation and Improved Leverage
Generated $329.3M in operating cash flow in 2025 and ended the year with $386.7M in cash and marketable securities (up ~$223.9M vs. end of 2024); net debt to adjusted EBITDA leverage reduced to less than 1x.
Jornay PM Rapid Growth and Market Momentum
Jornay prescriptions grew 20% YoY in 2025 (over 760,000 prescriptions), net revenue of $148.9M in 2025 (up 48% vs. pro forma 2024); Q4 prescriptions >200,000 (up 16% YoY); Q4 net revenue $45.9M (up 57% YoY); prescriber base >29,000 in Q4 (up 21% YoY); market share of long-acting branded methylphenidate ≈26% in Q4 (up 6.5 percentage points YoY).
Commercial Execution and Marketing Investments Paying Off
Expanded ADHD sales force (from ~125 to 180 reps) and added digital marketing reach (~70,000 HCPs targeted); average weekly Jornay prescriptions increased ~20% from July (13.8k) to December (16.6k), sustained into January (~16.8k) despite typical Q1 headwinds.
Durable Pain Portfolio Performance
Pain portfolio generated $631.7M in 2025, up 6% YoY, with all three core pain medicines delivering full-year growth (Belbuca $221.7M, up 5%; Xtampza ER $199.3M, up 4%; Nucynta franchise $196.3M, up 11%).
Strategic Capital Actions and Financial Flexibility
Closed a $980M syndicated credit facility in December (improved interest rate and debt terms; $580M initial term loan, $300M delayed draw, $100M revolver); repurchased $25M in shares in 2025 and have $150M remaining in buyback authorization.
Authorized Generic Agreement with Profit Share
Announced supply/quality agreements with Hikma to enable authorized generics of the Nucynta products; Hikma launched an authorized generic of Nucynta and is expected to launch Nucynta ER in Q1 2026; agreement includes significant profit share to monetize Nucynta franchise.
Reinforced Market Differentiation and RWE
Market research ranks Jornay as #1 in product differentiation among ADHD brands; completed four real-world evidence studies for Jornay and three across the pain portfolio to strengthen clinical evidence.
COLL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
COLL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $45.75 | $44.22 | -3.34% |
Nov 06, 2025 | $35.85 | $40.66 | +13.42% |
Aug 07, 2025 | $29.75 | $32.94 | +10.72% |
May 08, 2025 | $27.27 | $28.89 | +5.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Collegium Pharmaceutical (COLL) report earnings?
Collegium Pharmaceutical (COLL) is schdueled to report earning on May 07, 2026, TBA (Confirmed).
What is Collegium Pharmaceutical (COLL) earnings time?
Collegium Pharmaceutical (COLL) earnings time is at May 07, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is COLL EPS forecast?
COLL EPS forecast for the fiscal quarter 2026 (Q1) is 1.81.